Callisto Pharmaceuticals Announces Sponsored Research Agreement With M. D. Anderson Cancer Center To Further Development Of Degrasyn Anticancer Agents

NEW YORK--(BUSINESS WIRE)--May 10, 2006--Callisto Pharmaceuticals, Inc. (AMEX:KAL - News; FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, announced today that it has executed a sponsored research agreement with the University of Texas M. D. Anderson Cancer Center to support and accelerate development of the Company's Degrasyn class of cancer-fighting compounds.

Back to news